Evidence map›Paper›PMID 22180640›Full record

ArticleJournal of medical genetics2012

A novel microdeletion syndrome at 3q13.31 characterised by developmental delay, postnatal overgrowth, hypoplastic male genitals, and characteristic facial features.

Anna-Maja Molin, J Andrieux, D A Koolen, V Malan, M Carella, L Colleaux, V Cormier-Daire, A David, N de Leeuw, B Delobel and 25 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Journal of medical genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Experimental and therapeutic medicine · 2023
    Article
  8. Review
  9. Unique skeletal manifestations in patients with Primrose syndrome.European journal of medical genetics · 2020
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Adult expression of a 3q13.31 microdeletion.Molecular cytogenetics · 2014
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 9 countries.

Anna-Maja MolinDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. anna-maja.nystrom@slu.se
J Andrieux
D A Koolen
V Malan
M Carella
L Colleaux
V Cormier-Daire
A David
N de Leeuw
B Delobel
B Duban-Bedu
R Fischetto
F Flinter
S Kjaergaard
F Kok
A C Krepischi
C Le Caignec
C Mackie Ogilvie
S Maia
M Mathieu-Dramard
A Munnich
O Palumbo
F Papadia
R Pfundt
W Reardon
A Receveur
M Rio
L Ronsbro Darling
C Rosenberg
J Sá
L Vallee
C Vincent-Delorme
L Zelante
M-L Bondeson
G Annerén
Istituti di Ricovero e Cura a Carattere Scientifico · ITGroupe Hospitalier de l'Institut Catholique de Lille · FRGuy's and St Thomas' NHS Foundation Trust · GBHôpital Jeanne de Flandre · FRHôpital Necker-Enfants Malades · FRHospitais da Universidade de Coimbra · PTInserm · FROspedale Pediatrico Giovanni XXIII · ITRadboud University Medical Center · NLRigshospitalet · DKUniversité Paris Cité · FRUppsala University · SEAC Camargo Hospital · BRCentre Hospitalier Universitaire Amiens-Picardie · FRCentre Hospitalier Universitaire de Lille · FRGénétique Médicale & Génomique Fonctionelle · FRHospital Universitário da Universidade de São Paulo · BROur Lady's Hospital · IERadboud University Nijmegen · NLScience for Life Laboratory · SE

Funding

Wellcome Trust 086034
6 · The paper itself

Abstract

backgroundCongenital deletions affecting 3q11q23 have rarely been reported and only five cases have been molecularly characterised. Genotype-phenotype correlation has been hampered by the variable sizes and breakpoints of the deletions. In this study, 14 novel patients with deletions in 3q11q23 were investigated and compared with 13 previously reported patients.

methodsClinical data were collected from 14 novel patients that had been investigated by high resolution microarray techniques. Molecular investigation and updated clinical information of one cytogenetically previously reported patient were also included.

resultsThe molecular investigation identified deletions in the region 3q12.3q21.3 with different boundaries and variable sizes. The smallest studied deletion was 580 kb, located in 3q13.31. Genotype-phenotype comparison in 24 patients sharing this shortest region of overlapping deletion revealed several common major characteristics including significant developmental delay, muscular hypotonia, a high arched palate, and recognisable facial features including a short philtrum and protruding lips. Abnormal genitalia were found in the majority of males, several having micropenis. Finally, a postnatal growth pattern above the mean was apparent. The 580 kb deleted region includes five RefSeq genes and two of them are strong candidate genes for the developmental delay: DRD3 and ZBTB20.

conclusionA newly recognised 3q13.31 microdeletion syndrome is delineated which is of diagnostic and prognostic value. Furthermore, two genes are suggested to be responsible for the main phenotype.

Indexed as

Chromosome DeletionChromosomes, Human, Pair 3FaciesDevelopmental DisabilitiesFemaleGenetic Association StudiesGenitalia, MaleGrowth DisordersHumansMaleNerve Tissue ProteinsReceptors, Dopamine D3SyndromeTranscription FactorsDRD3 protein, humanNerve Tissue ProteinsReceptors, Dopamine D3Transcription FactorsZBTB20 protein, human

Identifiers

PMID22180640
PMCPMC3261728
OpenAlexW2115659307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.